论文部分内容阅读
目的 大面积接种甲型肝炎 (甲肝 )疫苗 ,建立群体免疫屏障 ,控制甲肝周期性流行效果评价。方法 对甲肝易感人群进行逐步免疫覆盖 ,并选择不同流行强度地区的人群进行抗 HAVIgG监测 ,分析评价甲肝疫苗累计接种率与人群免疫水平、甲肝发病率之间的相关性。结果 ① 1993～2 0 0 0年 8年间累计接种甲肝疫苗 198180 5人份 ,累计接种率为 34.15 % ,学龄前儿童、中小学生、15～4 5岁年龄组人群累计接种率分别为 84 .4 6 %、82 .2 3%、15 .14 %。 2 0 0 0年甲肝发病率仅为8.2 6 / 10万。② 1998年人群抗 HAVIgG阳性率为74 .2 4 % ,至 2 0 0 0年抗 HAVIgG阳性率达83.6 8% ,其中 2～ 4、6～ 8、13～ 15、2 0～、30～ 39岁年龄组的抗 HAVIgG阳性率已分别达到 74 .0 2 %、6 8.4 9%、79 .4 1%、85 .71%、90 .80 %。③相关与回归分析 ,人群甲肝疫苗累计接种率与甲肝抗体阳性率存在正相关关系 ,r全市 =0 .91,F =15 .10 ,P <0 .0 3。结论 大面积接种甲肝疫苗后 ,人群甲肝抗体阳性率达到 85 %左右 ,有效地构筑了甲肝的群体免疫屏障 ,阻断了甲肝后续的周期性流行 ,甲肝发病率控制在历史最低水平。
Objective To inoculate a large area of Hepatitis A (hepatitis A) vaccine to establish a population immune barrier, control of hepatitis A periodic epidemic evaluation. Methods The population of hepatitis A susceptible population was gradually immunized, and the population of different epidemic intensity areas was selected to monitor the anti-HAVIgG. The correlation between the cumulative vaccination rate of hepatitis A vaccine and the level of immunity and the incidence of hepatitis A were analyzed. Results ① The cumulative vaccination rate of hepatitis A vaccine was 1981805 for eight years from 1993 to 2000, the cumulative vaccination rate was 34.15%. The cumulative vaccination rates of preschool children, primary and middle school students, and 15 to 45 years old group were 84.4 6%, 82.2%, 15.14%. The incidence of hepatitis A in 2000 was only 8.26 / 100,000. ② In 1998, the positive rate of anti-HAVIgG was 74.24%, and the positive rate of anti-HAVIgG was 83.6% by 2000, of which 2 ~ 4,6 ~ 8,13 ~ 15,2 0 ~, 30 ~ 39 The positive rate of anti-HAV IgG in the age group reached 74.2%, 6 8.49%, 79.41%, 85.71% and 90.80% respectively. ③ Correlation and regression analysis, population cumulative vaccination rate of hepatitis A vaccine and hepatitis A antibody positive rate there is a positive correlation, r the city = 0 .91, F = 15 .10, P <0. Conclusion The positive rate of anti-HBeAg antibody is about 85% after hepatitis A vaccine is administered in a large area, effectively building a population immune barrier of hepatitis A, blocking the subsequent cyclical epidemic of hepatitis A and controlling the incidence of hepatitis A at the lowest level in history.